Brief: Lantern Pharma Announces Positive Data Highlighting The Anti-Tumor Potency Of Drug Candidate Lp-184 For Glioblastoma At The Society For Neuro-Oncology Annual Meeting
22/11/2022 13:14
Nov 22 (Reuters) - Lantern Pharma Inc. LTRN.O :
* LANTERN PHARMA ANNOUNCES POSITIVE DATA HIGHLIGHTING THE
ANTI-TUMOR POTENCY OF DRUG CANDIDATE LP-184 FOR GLIOBLASTOMA AT
THE SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
Source text for Eikon: ID:nBw2F61Ppa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments